Compared to the treatment with CIS+TGFβ1, GLT pretreatment reduced the viability by 60% compared to 0.5 μM CIS + TGFβ1 treatment and by 56% compared to 1 μM CIS + TGFβ1 treated CS-99 cells, and ~59% and ~58% decrease in cellular viability was observed in UMMT-ARK1 cells, respectively (Fig. 2A, B). Here, AURKA is linked to in situ carcinoma.